AADI - Aadi Bioscience GAAP EPS of -$0.77 revenue of $1M

Aadi Bioscience press release (NASDAQ:AADI): Q4 GAAP EPS of -$0.77. License Revenue of $1M. This compares to the $14M license revenue received in 4Q20, related to the non-refundable upfront payment for the rights and license granted to EOC Pharma under the license agreement for the further development and commercialization of FYARRO in the People’s Republic of China, Hong Kong Special Administration Region, Macao Special Administrative Region and Taiwan. As of Dec. 31, 2021, cash and cash equivalents totaled $149M.

For further details see:

Aadi Bioscience GAAP EPS of -$0.77, revenue of $1M